0
Myokardia Inc Banner Image

Myokardia Inc

  • Ticker MYOK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Myokardia Inc Logo Image
  • 51-200 Employees
  • Based in South San Francisco, CA
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functionalMore consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
REPORT RATINGS
4.8 / 5.0 (90)

Myokardia Inc reports have an aggregate usefulness score of 4.8 based on 90 reviews.

Myokardia Inc

Most Recent Annual Report

Myokardia Inc
MOST RECENT 2019 Annual Report and Form 10K

Older/Archived Annual Reports

Myokardia Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!